000165945 001__ 165945
000165945 005__ 20240229123217.0
000165945 0247_ $$2doi$$a10.1186/s12916-020-01797-2
000165945 0247_ $$2pmid$$apmid:33198768
000165945 0247_ $$2altmetric$$aaltmetric:94468991
000165945 037__ $$aDKFZ-2020-02496
000165945 041__ $$aeng
000165945 082__ $$a610
000165945 1001_ $$aEscala-Garcia, Maria$$b0
000165945 245__ $$aBreast cancer risk factors and their effects on survival: a Mendelian randomisation study.
000165945 260__ $$aHeidelberg [u.a.]$$bSpringer$$c2020
000165945 3367_ $$2DRIVER$$aarticle
000165945 3367_ $$2DataCite$$aOutput Types/Journal article
000165945 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1607691344_3919
000165945 3367_ $$2BibTeX$$aARTICLE
000165945 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000165945 3367_ $$00$$2EndNote$$aJournal Article
000165945 520__ $$aObservational studies have investigated the association of risk factors with breast cancer prognosis. However, the results have been conflicting and it has been challenging to establish causality due to potential residual confounding. Using a Mendelian randomisation (MR) approach, we aimed to examine the potential causal association between breast cancer-specific survival and nine established risk factors for breast cancer: alcohol consumption, body mass index, height, physical activity, mammographic density, age at menarche or menopause, smoking, and type 2 diabetes mellitus (T2DM).We conducted a two-sample MR analysis on data from the Breast Cancer Association Consortium (BCAC) and risk factor summary estimates from the GWAS Catalog. The BCAC data included 86,627 female patients of European ancestry with 7054 breast cancer-specific deaths during 15 years of follow-up. Of these, 59,378 were estrogen receptor (ER)-positive and 13,692 were ER-negative breast cancer patients. For the significant association, we used sensitivity analyses and a multivariable MR model. All risk factor associations were also examined in a model adjusted by other prognostic factors.Increased genetic liability to T2DM was significantly associated with worse breast cancer-specific survival (hazard ratio [HR] = 1.10, 95% confidence interval [CI] = 1.03-1.17, P value [P] = 0.003). There were no significant associations after multiple testing correction for any of the risk factors in the ER-status subtypes. For the reported significant association with T2DM, the sensitivity analyses did not show evidence for violation of the MR assumptions nor that the association was due to increased BMI. The association remained significant when adjusting by other prognostic factors.This extensive MR analysis suggests that T2DM may be causally associated with worse breast cancer-specific survival and therefore that treating T2DM may improve prognosis.
000165945 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000165945 588__ $$aDataset connected to CrossRef, PubMed,
000165945 7001_ $$aMorra, Anna$$b1
000165945 7001_ $$aCanisius, Sander$$b2
000165945 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b3$$udkfz
000165945 7001_ $$aKar, Siddhartha$$b4
000165945 7001_ $$aZheng, Wei$$b5
000165945 7001_ $$aBojesen, Stig E$$b6
000165945 7001_ $$aEaston, Doug$$b7
000165945 7001_ $$aPharoah, Paul D P$$b8
000165945 7001_ $$00000-0002-2228-429X$$aSchmidt, Marjanka K$$b9
000165945 773__ $$0PERI:(DE-600)2131669-7$$a10.1186/s12916-020-01797-2$$gVol. 18, no. 1, p. 327$$n1$$p327$$tBMC medicine$$v18$$x1741-7015$$y2020
000165945 909CO $$ooai:inrepo02.dkfz.de:165945$$pVDB
000165945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000165945 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000165945 9141_ $$y2020
000165945 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC MED : 2018$$d2020-09-05
000165945 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-05
000165945 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-05
000165945 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-09-05
000165945 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-09-05
000165945 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-09-05
000165945 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2020-09-05
000165945 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-09-05
000165945 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-09-05
000165945 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-09-05
000165945 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-05
000165945 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-05
000165945 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-09-05
000165945 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-09-05
000165945 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-09-05
000165945 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-05
000165945 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-05
000165945 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBMC MED : 2018$$d2020-09-05
000165945 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-05
000165945 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-05
000165945 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000165945 980__ $$ajournal
000165945 980__ $$aVDB
000165945 980__ $$aI:(DE-He78)C020-20160331
000165945 980__ $$aUNRESTRICTED